Latest Matter News

Plato Income Maximiser matched its benchmark with a 7.2% portfolio return in FY26 while maintaining its highest monthly dividend rate since listing. Profit after tax fell to A$41.8 million as investment gains dropped sharply from the prior year.

Overwatch Technologies is seeking A$8 million to fund an ASX listing and expand its drone-enabled maritime intelligence business. The company has A$3.8 million of contracted orders, but has yet to recognise revenue and reported an inaugural loss of A$857,604.

Odyssey Gold has terminated its toll milling agreement with Gylden Resources after a dispute with its Tuckanarra joint venture partner over the authority to sign the deal. A replacement agreement remains under discussion, leaving the project’s proposed processing pathway unresolved.

Euroz Hartleys says several conditions for its A$145 million sale of the Capital Markets business to BMO have now been satisfied, leaving shareholder approval and Canadian Bank Act approval among the key remaining gates. Completion remains on track for the December quarter.

ReNerve has received supportive FDA feedback on the preclinical and testing pathway for its NervAlign Nerve Guide Matrix. The guidance sharpens the route towards a US submission, but does not amount to clearance and leaves the submission timetable open.

Minerals Exploration has shifted decisively into New Zealand gold and tungsten, but its annual report flags a $2.66 million loss and a material uncertainty over its ability to continue without further funding. Exploration results are encouraging, though the company has yet to establish a mineral resource or economic discovery.

Lion Rock Minerals has reported repeated shallow heavy-mineral zones with significant monazite at Minta Est, including up to 1.94% estimated TREO and 3.62% calculated monazite in recovered concentrate. Early magnetic-separation tests also concentrated up to 84.1% of calculated TREO into less than 27% of recovered heavy-mineral mass, although the results remain preliminary and HMC-based.

Bubs Australia delivered 9.2% revenue growth and a sharp underlying EBITDA improvement in FY26, but statutory losses, weaker margins and negative operating cash flow expose the cost of its expansion. Permanent US FDA authorisation removes a major regulatory hurdle, while the annual report still flags material uncertainty around ongoing funding and cash generation.

Core Lithium has moved Finniss into the next phase of its restart, producing first spodumene concentrate and targeting an initial shipment in the December quarter. The company ended September with A$199.7 million in cash, while BP33 development and high-grade exploration continued in parallel.

Rio Tinto’s third-quarter production update put its growth assets in the spotlight, with Oyu Tolgoi copper up 29% year to date and Simandou reaching a 10 Mtpa annualised run-rate. The miner maintained its 2026 production and unit-cost guidance while reporting more than US$2 billion of capital release arrangements.

Clever Culture Systems has appointed PSC Biotech as its sole sales agent for APAS Independence across pharmaceutical manufacturing markets in the US, Canada and Singapore. The agreement expands CCS’s reach beyond its direct focus on major global drugmakers, but any material revenue uplift is not expected before FY28.

Finbar has completed its largest-ever apartment development by lot count, issuing titles for the 342-lot Garden Towers project in East Perth and opening the way for settlements. The 50% joint venture is 82% sold, with $210 million in sales recorded to date and revenue recognition expected in H1 FY27.